Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2011-08-30
2011-08-30
Kim, Jennifer M (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
C514S524000, C514S493000, C514S616000, C514S619000
Reexamination Certificate
active
08008348
ABSTRACT:
This invention provides: 1) a method of treating a subject suffering from a muscle wasting disorder; 2) a method of preventing a muscle wasting disorder in a subject; 3) a method of treating, preventing, suppressing, inhibiting or reducing muscle loss in a subject suffering from a muscle wasting disorder; 4) a method of treating, preventing, inhibiting, reducing or suppressing muscle wasting in a subject suffering from a muscle wasting disorder; and/or 5) a method of treating, preventing, inhibiting, reducing or suppressing muscle protein catabolism in a subject suffering from a muscle wasting disorder, by administering to the subject a selective androgen receptor modulator (SARM) and/or an analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, prodrug, polymorph, impurity or crystal of said SARM compound, or any combination thereof.
REFERENCES:
patent: 3875229 (1975-04-01), Gold
patent: 4139638 (1979-02-01), Neri et al.
patent: 4191775 (1980-03-01), Glen
patent: 4239776 (1980-12-01), Glen et al.
patent: 4282218 (1981-08-01), Glen et al.
patent: 4386080 (1983-05-01), Crossley et al.
patent: 4465507 (1984-08-01), Konno et al.
patent: 4636505 (1987-01-01), Tucker
patent: 4880839 (1989-11-01), Tucker
patent: 5162504 (1992-11-01), Horoszewicz
patent: 5609849 (1997-03-01), Kung
patent: 5656651 (1997-08-01), Sovak et al.
patent: 6019957 (2000-02-01), Miller et al.
patent: 6071957 (2000-06-01), Miller et al.
patent: 6160011 (2000-12-01), Miller et al.
patent: 6482861 (2002-11-01), Miller et al.
patent: 6492554 (2002-12-01), Dalton et al.
patent: 6569896 (2003-05-01), Dalton et al.
patent: 6995284 (2006-02-01), Dalton et al.
patent: 7547728 (2009-06-01), Steiner et al.
patent: 2001/0012839 (2001-08-01), Miller et al.
patent: 0 040 932 (1981-02-01), None
patent: 0 100 172 (1984-02-01), None
patent: 000 2892 (1985-02-01), None
patent: 00198352 (1989-01-01), None
patent: 0253 503 (1991-12-01), None
patent: 1360001 (1970-03-01), None
patent: 52-128329 (1977-10-01), None
patent: 54-63047 (1980-12-01), None
patent: WO 95/19770 (1995-07-01), None
patent: WO 98 05962 (1998-02-01), None
patent: WO 98/53826 (1998-12-01), None
patent: WO 98/55153 (1998-12-01), None
patent: WO 01 27622 (2001-04-01), None
patent: WO 01 28990 (2001-04-01), None
patent: WO 01 34563 (2001-05-01), None
patent: WO 02 00617 (2002-01-01), None
patent: WO 02/16310 (2002-02-01), None
patent: WO 2005/000794 (2005-01-01), None
Souillac et al. Characterization of Delivery Systems, Differential Scanning Calorimetry, pp. 217-218 (in Encyclopedia of Controlled Drug Delivery, 1999, John Wiley & Sons, pp. 212-227).
Vippagunta et al. Advanced Drug Delivery Reviews, 48 (2001), pp. 3-26.
U.S. Appl. No. 09/935,044, filed Aug. 23, 2001, Dalton et al.
U.S. Appl. No. 09/935,045, filed Aug. 23, 2001, Dalton et al.
U.S. Appl. No. 09/644,970, filed Aug. 2, 2000, Dalton et al.
U.S. Appl. No. 10/298,229, filed Nov. 28, 2002, Miller et al.
U.S. Appl. No. 10/270,232, filed Oct. 15, 2002, Dalton et al.
U.S. Appl. No. 10/277,108, filed Oct. 23, 2002, Dalton et al.
U.S. Appl. No. 10/270,732, filed Oct. 15, 2002, Dalton et al.
Eliason et al., “High Throughput Fluorescence Polarization-Based Screening Assays for the Identification of Novel Nuclear Receptor Ligands,” Abstracts of Papers, 223rd ACS National Meeting, Orlando, FL, United States, (2002), Apr. 7, 2002.
Berger et al., “Concepts and limitations in the application of radiolabeled antiandrogens, estrogens, or androgens as isotropic scanning agents for the prostate”, Invest Urol, (1975), 1391, 10-16.
Howard Tucker and Glynne J. Chesterson, J. Med Chem. 1988, 31, pp. 885-887, “Resolution of the Nonsteroidal Antiandrogen—4′-Cyano-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-3′ -(trifluoromethyl)-propionanilide and the Determination of the Absolute Configuration of the Active Enantiomer”.
D. McKillop, et al., “Enantioselective metabolism and pharmacokinetics of Casodex in the male rat”, Xenobiotica, 1995, vol. 25, No. 6, 623-634.
Leonid Kirkovsky, et al., “[125I]-Radionated Bicalutamide Analogs as Potential Imaging Agents for Prostate Cancer”, Poster Presentation MEDI 155, 214th ACS National Meeting, Las Vegas, NV, Sep. 7-11, 1997, Department of Pharmaceutical Sciences, University of Tennessee, Memphis, TN 38163.
David T. Baird and Anna F. Glasier, “Hormonal Contraception—Drug Therapy”, The New England Journal of Medicine , May 27, 1993. pp. 1543-1549.
F.C. W. Wu. “Male Contraception: Current Status and Future Prospects”, Clinical Endocrinology, (1988), 29, pp. 443-465.
World Health Organisation Task Force on Methods for the Regulation of Male Fertility, “Contraceptive efficacy of testosterone-induced azoospermia in normal men”, The Lancet, vol. 336, Oct. 20, 1990, pp. 955-959and 1517-1518.
C. G. Francisco, et al., “Long-acting contraceptive agents: testosterone esters of unsaturated acids”, Steroids, Jan. 1990, vol. 55, Butterworths.
John M. Hoberman and Charles E. Yesalis, “The History of Synthetic Testosterone”, Scientific American, Feb. 1995, pp. 76-81.
Leonid Kirkovsky, et al., “Approaches to Irreversible non-steroidal chiral antiandrogens”, Department of Pharmaceutical Sciences, University of Tennessee, 47th Southeast/51st Southwest Joint Regional Meeting of the American Chemical Society, Memphis, TN, Nov. 29-Dec. 1, 1995.
Edwards JP, Higuchi RI, Winn DT, Pooley CLF, Caferro TR, Hamann LG, Zhi L, Marschke KB, Goldman ME, and Jones TK. Nonsteroidal androgen receptor agonists based on 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one. Bioorg. Med. Chem. Lett., 9: 1003, 1999.
Zhi L, Tegley CM, Marschke KB, and Jones TK. Switching androgen receptor antagonists to agonists by modifying C-ring substituents on piperidino[3,2-g]quinolone. Bioorg. Med. Chem. Lett., 9: 1009, 1999.
Higuchi RI, Edwards JP, Caferro TR, Ringgenberg JD, Kong JW, Hamann LG, Arienti KL, Marschke KB, Davis RL, Farmer LJ, and Jones TK. 4-Alkyl- and 3,4-diaklyl-1,2,3,4-tetrahydro-8-pyridono[5,6-g]quinolines: potent, nonsteroidal androgen receptor agonists. Bioorg. Med. Chem. Lett., 9:1335, 1999.
Hamann LG, Mani NS, Davis RL., Wang XN, Marschke KB, and Jones TK. Discovery of a potent, orally active nonsteroidal androgen receptor agonist: 4-ethyl-1,2,3,4-tetrahydro-6-(trifluoromethyl)-8-pyridono[5,6-g]-quinoline (LG121071). J. Med. Chem., 42: 210, 1999.
Rosen J, Day A, Jones TK, Jones ET, Nadzan AM, and Stein RB. Intracellular receptors and signal transducers and activators of transcription superfamilies: novel targets for small-molecule drug discovery. J. Med. Chem.. 38: 4855, 1995.
Dalton JT, Mukherjee A, Zhu Z, Kirkovsky L, and Miller DD. Discovery of Nonsteroidal Androgens. Biochem. Biophys. Res. Commun.,244(1 ):1-4, 1998.
Edwards JP, West SJ, Pooley CLF, Marschke KB, Farmer LJ, and Jones TK. New nonsteroidal androgen receptor modulators based on 4-(trifluoromethyl)-2-(1H)-Pyrololidino[3,2-g]quinolone. Bioorg. Med. Chem. Lett., 8: 745, 1998.
Buchwald, et Long-term, continuous intravenous heparin administration by an implantable infusion pump in ambulatory patients with recurrent venous thrombosis.Surgery, 1980 88(4):507-16.
Goodson, et al (1984) Medical Applications of Controlled Release vol. 2, 115-138.
Langer, et al New methods of drug delivery. Science. Sep. 28, 1990; 249(4976):1527-33. Review.
Saudek, et al A preliminary trial of the programmable implantable medication system for insulin delivery. N Engl J Med. Aug. 31, 1989; 321(9):574-9.
Treat, et al (1989) Liposomes in the Therapy of Infectious Disease and Cancer 353-365.
Handelsman, DJ, “Bridging the gender gap in contraception: another hurdle cleared”, The Medical Journal of Australia, vol. 154, Feb. 18, 1996, p. 230-233.
La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH. “Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy.” Nature. Jul 4, 1991;352(63
Dalton James T.
Miller Duane D.
Steiner Mitchell S.
Veverka Karen A.
Cohen Mark S.
Kim Jennifer M
Pearl Cohen Zedek Latzer LLP
University of Tennessee Research Foundation
LandOfFree
Treating muscle wasting with selective androgen receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treating muscle wasting with selective androgen receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treating muscle wasting with selective androgen receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2641038